GlycoVaxyn is a private Swiss biotechnology company developing a broad portfolio of novel bioconjugate vaccines to prevent and treat common, severe bacterial infections using its proprietary glycoprotein technology.
View Top Employees from Glycovaxyn AG| Website | http://www.glycovaxyn.com/ |
| Revenue | $6.6 million |
| Funding | $22 million |
| Employees | 4 (4 on RocketReach) |
| Founded | 2004 |
| Address | Grabenstrasse 3, Schlieren, Zurich 8952, CH |
| Phone | +41 44 733 85 85 |
| Technologies | |
| Industry | Biotechnology, Hospitals and Health Care, Pharmaceuticals, Healthcare, Science and Engineering, Manufacturing, Drug Manufacturing & Research, Pharmaceutical, Health Care |
| Web Rank | 24 Million |
| Keywords | Glycovaxin |
| Competitors | Crown Bioscience, Fluofarma, QGel, Redbiotec AG |
| SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Glycovaxyn AG employee's phone or email?
Glycovaxyn AG Questions
The Glycovaxyn AG annual revenue was $6.6 million in 2023.
4 people are employed at Glycovaxyn AG.
Glycovaxyn AG is based in Schlieren, Zurich.
The NAICS codes for Glycovaxyn AG are [32541, 3254, 325, 32].
The SIC codes for Glycovaxyn AG are [2834, 283, 28].
Top Glycovaxyn AG Employees
Related Companies
